Skip directly to content

Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

Multidrug-resistant TB (MDR-TB) is a growing problem around the world, and is difficult to treat. In 2016, the World Health Organization (WHO) recommended a shorter regimen for treating MDR-TB. Now, data from a randomized controlled trial are available. This new brief from TAG and DR-TB STAT explains what the shorter regimen is, who can receive it, and its advantages and disadvantages. 

If you want to learn even more, check out the webinar we held on the phase III trial of the shorter regimen and on the phase III trial of newer TB drug, delamanid, on this page.